OneHealthdrugs focuses on the discovery of new drugs against vector borne parasitic disease (Leishmaniasis, Trypanosomiasis, others) infecting humans and animals in Europe and beyond. By designing new, more effective, and less toxic drugs, OHD hopes to reduce the release of drugs into the environment that can cause negative impacts on ecosystems. OHD is funded
by COST (European Cooperation in Science and Technology), a funding agency for research and innovation networks. More information: mariapaola.costi@unimore.it. https://tinyurl.com/mrybbxkx
COST
What is COST?
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
OneHealthdrugs CA21111
Title:
One Health drugs against parasitic vector borne diseases in Europe and beyond
